Entrada Therapeutics (TRDA) Common Equity (2020 - 2026)

Entrada Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $270.9 million for Q1 2026.

• On a quarterly basis, Common Equity fell 35.09% year-over-year to $270.9 million in Q1 2026; TTM through Mar 2026 was $270.9 million, a 35.09% decrease from a year earlier, with the FY2025 full-year figure at $306.1 million, down 28.59% from the prior year.
• Common Equity eased to $270.9 million in Q1 2026 per TRDA's latest filing, from $306.1 million in the prior quarter.
• Across five years, Common Equity topped out at $429.9 million in Q2 2024 and bottomed at $206.9 million in Q2 2023.
• The 5-year median for Common Equity is $270.9 million (2026), against an average of $304.1 million.
• Across the five-year window, Common Equity surged 658.48% in 2022 and slumped 35.09% in 2026, its largest moves.
• Year by year, Common Equity stood at $212.6 million in 2022, then increased by 14.02% to $242.4 million in 2023, then jumped by 76.88% to $428.7 million in 2024, then decreased by 28.59% to $306.1 million in 2025, then slipped by 11.52% to $270.9 million in 2026.
• Per Business Quant, the three latest TRDA Common Equity figures stand at $270.9 million (Q1 2026), $306.1 million (Q4 2025), and $340.7 million (Q3 2025).